source
- FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, pricing set at $425,000 per yearThe U.S. Food and Drug Administration has granted approval to Trutakna, a new therapy from Vera Therapeutics, for the treatment of IgA nephropathy. IgA nephropathy is a kidney disorder where immun…
- Sino Biopharm signs separate respiratory partnership deals with AstraZeneca and GSKSino Biopharm announced it has entered into two distinct agreements with UK-based pharmaceutical companies focused on respiratory medicines. One agreement involves licensing its investigational PD…